A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and
safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or
refractory ALCL.